Becker's Hospital Review: Dr. Guru Sonpavde, Medical Director of Genitourinary Oncology (GU) at AdventHealth Cancer Institute Dr. Guru Sonpavde, Medical Director of Genitourinary Oncology (GU), AdventHealth Cancer Institute joins the podcast to dive deep into some of the clinical research that AdventHealth is pioneering and ...
Dr. Guru Sonpavde, Medical Director of Genitourinary Oncology (GU) at AdventHealth Cancer Institute Dr. Guru Sonpavde emphasized the importance of better understanding how genetic mutations influence the treatment of cancer care, particularly GU cancers. The American Journal of Managed Care: Dr Guru Sonpavde on the Potential of Nivolumab Plus Chemotherapy in Urothelial Carcinoma Guru Sonpavde, MD, medical director of genitourinary oncology at the AdventHealth Cancer Institute, discussed the promising findings of the CheckMate 901 trial exploring the potential of nivolumab ...
dr guru sonpavde, Dr Guru Sonpavde on the Potential of Nivolumab Plus Chemotherapy in Urothelial Carcinoma ksn.com: Vial adds Dr. Guru Sonpavde of the Dana-Farber Cancer Institute to their Oncology CRO Advisory Board SAN FRANCISCO, /PRNewswire/ -- Dr. Guru Sonpavde is the Bladder Cancer Director at the Dana-Farber Cancer Institute, an Associate Professor of Medicine at Harvard Medical School, and a ... Vial adds Dr. Guru Sonpavde of the Dana-Farber Cancer Institute to their Oncology CRO Advisory Board
